WASHINGTON — The U.S. government announced on Monday that it will award $265 million to Fujifilm Holdings to help expand vaccine production to combat the coronavirus pandemic.
President Donald Trump made the announcement when he visited the Bioprocess Innovation Center at Fujifilm Diosynth Biotechnologies in Morrisville, North Carolina.
According to the Japanese company, it will invest to increase vaccine manufacturing capacity at its facility in Texas by autumn before starting mass production in early 2021.
Fujifilm Diosynth Biotechnologies CEO Martin Meeson, right, speaks as President Donald Trump wears a face mask as he participates in a tour of Bioprocess Innovation Center at Fujifilm Diosynth Biotechnologies in Morrisville, U.S. on July 27.
In addition to Novavax, the U.S. government has awarded financial support to other vaccine developers including Pfizer.